Dabigatran

Generic Name
Dabigatran
Brand Names
Dabigatran Etexilate Leon Farma, Dabigatran Etexilate Accord, Pradaxa
Drug Type
Small Molecule
Chemical Formula
C25H25N7O3
CAS Number
211914-51-1
Unique Ingredient Identifier
I0VM4M70GC
Background

Dabigatran is the active form of the orally bioavailable prodrug dabigatran etexilate.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Dabigatran for the Adjunctive Treatment of Staphylococcus Aureus Bacteremia

First Posted Date
2024-10-21
Last Posted Date
2024-10-21
Lead Sponsor
Emily McDonald
Target Recruit Count
300
Registration Number
NCT06650501
Locations
🇨🇦

McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital), Montreal, Quebec, Canada

The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)

First Posted Date
2024-06-10
Last Posted Date
2024-06-10
Lead Sponsor
Rigshospitalet, Denmark
Target Recruit Count
324
Registration Number
NCT06449469
Locations
🇩🇰

Aarhus University Hospital, Skejby, Aarhus, Denmark

🇩🇰

Rigshospitalet, Copenhagen, Denmark

A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France

First Posted Date
2023-05-01
Last Posted Date
2024-05-17
Lead Sponsor
Pfizer
Target Recruit Count
3691397
Registration Number
NCT05838664
Locations
🇫🇷

Pfizer Investigational Site, Paris, France

PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants

First Posted Date
2021-10-01
Last Posted Date
2024-03-29
Lead Sponsor
Pfizer
Target Recruit Count
24
Registration Number
NCT05064800
Locations
🇺🇸

Research Centers of America ( Hollywood ), Hollywood, Florida, United States

High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France

First Posted Date
2021-09-09
Last Posted Date
2024-11-05
Lead Sponsor
Pfizer
Target Recruit Count
1
Registration Number
NCT05038228
Locations
🇬🇧

Pfizer Investigator, London, United Kingdom

Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea

First Posted Date
2021-08-26
Last Posted Date
2023-08-03
Lead Sponsor
Pfizer
Target Recruit Count
55759
Registration Number
NCT05022563
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of

🇰🇷

Sungkyunkwan University, Suwon-si, Korea, Republic of

Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty

First Posted Date
2021-05-07
Last Posted Date
2021-05-07
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
1000000
Registration Number
NCT04878497
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects

First Posted Date
2021-03-22
Last Posted Date
2021-03-22
Lead Sponsor
Lumosa Therapeutics Co., Ltd.
Target Recruit Count
64
Registration Number
NCT04809818
Locations
🇺🇸

Lumosa Phase 1 Unit, Cypress, California, United States

NOAC Portuguese Real World Study

First Posted Date
2021-03-22
Last Posted Date
2023-04-05
Lead Sponsor
Pfizer
Registration Number
NCT04808934

A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Dabigatran
Drug: Selpercatinib
First Posted Date
2021-03-04
Last Posted Date
2024-05-24
Lead Sponsor
Loxo Oncology, Inc.
Target Recruit Count
36
Registration Number
NCT04782076
Locations
🇺🇸

Covance Clinical Research Inc, Daytona Beach, Florida, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy